Avalo Therapeutics, Inc. cash flow to debt ratio of -2.12K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Avalo Therapeutics, Inc.'s free cash flow has decreased 4.90% from $-49.06M last year to $-51.46M, signaling decreasing performance

Avalo Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Avalo Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Avalo Therapeutics, Inc. has a net cash position, so leverage is healthy.

Avalo Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Avalo Therapeutics, Inc.'s profit margin has decreased (2.03K%) in the last year from -7.97K% to -170.06K%, signaling decreasing performance

Avalo Therapeutics, Inc.'s short-term assets of $105.29M exceed its short-term liabilities of $12.94M

Avalo Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Avalo Therapeutics, Inc.'s return on equity of -58.03%, is lower than 15.00%, indicating bad performance

Avalo Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Avalo Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Avalo Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Avalo Therapeutics, Inc. has negative free cash flow, indicating cash burn

Avalo Therapeutics, Inc.'s yearly earnings has decreased 122.78% since last year from $-35.13M to $-78.26M, signaling decreasing performance

Avalo Therapeutics, Inc.'s yearly revenue has decreased 86.62% since last year from $441.00K to $59.00K, signaling decreasing performance

ROIC -19.44% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Avalo Therapeutics, Inc.'s 3-year revenue CAGR of -85.16% is negative, indicating declining revenue over the past 3 years

Avalo Therapeutics, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Avalo Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Avalo Therapeutics, Inc. has insufficient data to evaluate this check.

Avalo Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Avalo Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Avalo Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Avalo Therapeutics, Inc. is overvalued relative to its fair value price of -0.45 based on Earnings Fair Value model

Avalo Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Avalo Therapeutics, Inc. has a price-to-book ratio of 1.92x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Avalo Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue